HOOKIPA Pharma Inc. (HOOK) shares plunged 5.82% in the after-hours on Friday and closed the trading at $2.75. However, in the regular trading session of Friday, HOOK’s stock lost 7.01%. HOOK shares have fallen 73.72% over the last 12 months, and they have moved down 10.43% in the past week. Over the past three months, the stock has lost 56.87%, while over the past six months, it has sunk 77.96%.
Let’s discuss its recent news and developments.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
HOOK participation in the upcoming event
HOOKIPA Pharma Inc. (HOOK) will participate in virtual investor meetings and present at The JMP Securities Hematology and Oncology Summit that will be held on December 6-7, 2021.
HOOK participation in a recent past event
HOOKIPA Pharma Inc. (HOOK), participated in the Stifel 2021 Virtual Healthcare Conference which was held on November 15th – 17, 2021.
HOOK latest financial results
On November 10, 2021, HOOKIPA Pharma Inc. (HOOK) reported financial results for the third quarter of 2021.
Q3 2021 financial highlights
- HOOK total revenue for Q3 2021 was $3.9 million compared to $4.0 million for the three months ended September 30, 2020.
- Total operating expenses were $25.04 million in Q3 2021 compared to $20.5 million in Q3 2020.
- It suffered a net loss of $20.0 million for the three months ended September 30, 2021, compared to a net loss of $13.6 million for the three months ended September 30, 2020.
- HOOKIPA ended Q3 2021 with cash, cash equivalents, and restricted cash of $82.7 million compared to $143.2 million as of December 31, 2020.
HOOK update about HB-200 program
On November 09, 2021, HOOKIPA Pharma Inc. (HOOK), announced that it is advancing HB-201 to Phase 2, to be evaluated in combination with pembrolizumab as 1st– or 2nd-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).
Interim Phase 1 data showed that HB-200 monotherapy is highly effective at expanding T cells, has a favorable tolerability profile, and has promising, early anti-tumor activity. HOOKIPA observed three partial responses in treated patients (including one confirmed and one unconfirmed in an ongoing patient) and one ongoing patient with a near partial response (29 per cent tumor shrinkage).
Publication of HOOK review article
On October 14, 2021, HOOKIPA Pharma Inc. (HOOK), announced the publication of a comprehensive review article on arenaviral immunotherapies in the peer-reviewed online journal, Frontiers in Oncology. The article reinforces the potential of HOOKIPA’s versatile arenavirus platform as a promising strategy to elicit potent, tumour-specific T cell responses and help address critical unmet needs in the treatment of cancer.
Well, as of this writing, there is no recent news or development behind its poor performance on Friday. we are not sure how it will perform on Monday.